JP2002518373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002518373A5 JP2002518373A5 JP2000554703A JP2000554703A JP2002518373A5 JP 2002518373 A5 JP2002518373 A5 JP 2002518373A5 JP 2000554703 A JP2000554703 A JP 2000554703A JP 2000554703 A JP2000554703 A JP 2000554703A JP 2002518373 A5 JP2002518373 A5 JP 2002518373A5
- Authority
- JP
- Japan
- Prior art keywords
- penten
- isopropoxy
- pyridyl
- amine
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 10
- 208000024827 Alzheimer disease Diseases 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- RPCVIAXDAUMJJP-HOSRBBHYSA-N (e,2r)-n-methyl-5-(5-propan-2-yloxypyridin-3-yl)pent-4-en-2-amine Chemical compound CN[C@H](C)C\C=C\C1=CN=CC(OC(C)C)=C1 RPCVIAXDAUMJJP-HOSRBBHYSA-N 0.000 description 5
- RPCVIAXDAUMJJP-PZBABLGHSA-N ispronicline Chemical compound CN[C@@H](C)C\C=C\C1=CN=CC(OC(C)C)=C1 RPCVIAXDAUMJJP-PZBABLGHSA-N 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 206010036631 Presenile dementia Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 206010013932 dyslexia Diseases 0.000 description 2
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 0 CC1=IC(*)=C(C(*)=C(*)**)C(*)=*1 Chemical compound CC1=IC(*)=C(C(*)=C(*)**)C(*)=*1 0.000 description 1
- 206010020651 Hyperkinesia Diseases 0.000 description 1
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9828598A | 1998-06-16 | 1998-06-16 | |
| US09/098,133 | 1998-06-16 | ||
| US09/098,285 | 1998-06-16 | ||
| US09/098,133 US6232316B1 (en) | 1998-06-16 | 1998-06-16 | Methods for treatment of CNS disorders |
| PCT/US1999/012340 WO1999065876A1 (en) | 1998-06-16 | 1999-06-03 | Aryl substituted olefinic amines and their use as cholinergic receptors agonists |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008130502A Division JP4972608B2 (ja) | 1998-06-16 | 2008-05-19 | アリール置換オレフィンアミンと、コリン受容体アゴニストとしてのアリール置換オレフィンアミンの使用 |
| JP2008130504A Division JP4896923B2 (ja) | 1998-06-16 | 2008-05-19 | アリール置換オレフィンアミンと、コリン受容体アゴニストとしてのアリール置換オレフィンアミンの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002518373A JP2002518373A (ja) | 2002-06-25 |
| JP2002518373A5 true JP2002518373A5 (https=) | 2008-07-10 |
| JP4240815B2 JP4240815B2 (ja) | 2009-03-18 |
Family
ID=26794206
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000554703A Expired - Fee Related JP4240815B2 (ja) | 1998-06-16 | 1999-06-03 | アリール置換オレフィンアミンと、コリン受容体アゴニストとしてのアリール置換オレフィンアミンの使用 |
| JP2008130504A Expired - Fee Related JP4896923B2 (ja) | 1998-06-16 | 2008-05-19 | アリール置換オレフィンアミンと、コリン受容体アゴニストとしてのアリール置換オレフィンアミンの使用 |
| JP2008130502A Expired - Fee Related JP4972608B2 (ja) | 1998-06-16 | 2008-05-19 | アリール置換オレフィンアミンと、コリン受容体アゴニストとしてのアリール置換オレフィンアミンの使用 |
| JP2010135746A Pending JP2010229149A (ja) | 1998-06-16 | 2010-06-15 | アリール置換オレフィンアミンと、コリン受容体アゴニストとしてのアリール置換オレフィンアミンの使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008130504A Expired - Fee Related JP4896923B2 (ja) | 1998-06-16 | 2008-05-19 | アリール置換オレフィンアミンと、コリン受容体アゴニストとしてのアリール置換オレフィンアミンの使用 |
| JP2008130502A Expired - Fee Related JP4972608B2 (ja) | 1998-06-16 | 2008-05-19 | アリール置換オレフィンアミンと、コリン受容体アゴニストとしてのアリール置換オレフィンアミンの使用 |
| JP2010135746A Pending JP2010229149A (ja) | 1998-06-16 | 2010-06-15 | アリール置換オレフィンアミンと、コリン受容体アゴニストとしてのアリール置換オレフィンアミンの使用 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1086082B9 (https=) |
| JP (4) | JP4240815B2 (https=) |
| KR (1) | KR100593433B1 (https=) |
| AT (1) | ATE273956T1 (https=) |
| AU (1) | AU4230799A (https=) |
| BR (1) | BR9911325A (https=) |
| CA (3) | CA2709735A1 (https=) |
| DE (1) | DE69919537T2 (https=) |
| DK (1) | DK1086082T3 (https=) |
| ES (1) | ES2228054T3 (https=) |
| PT (1) | PT1086082E (https=) |
| WO (1) | WO1999065876A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6979695B2 (en) * | 1996-04-23 | 2005-12-27 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| CA2709735A1 (en) * | 1998-06-16 | 1999-12-23 | Targacept, Inc. | Aryl substituted olefinic amines and their use as cholinergic receptors agonists |
| EP1185514A1 (en) * | 1999-06-07 | 2002-03-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| CA2383307A1 (en) * | 1999-08-31 | 2001-03-08 | Jared Miller Wagner | Arylalkyloxyalkylamines and arylalkylthioalkylamines, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors |
| WO2001082978A2 (en) * | 2000-05-01 | 2001-11-08 | Targacept, Inc. | Imaging of nicotinic acetylcholine receptor subtypes |
| US6432954B1 (en) * | 2000-07-14 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| HUP0501017A3 (en) | 2001-12-14 | 2010-06-28 | Targacept | Methods and compositions for treatment of central nervous system disorders |
| US8580842B2 (en) | 2003-09-30 | 2013-11-12 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
| WO2005037832A2 (en) | 2003-10-15 | 2005-04-28 | Targacept, Inc. | Azabicycyclic compounds for relieving pain and treating central nervous system disorders |
| UA88792C2 (ru) | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
| US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
| TWI389889B (zh) | 2006-05-09 | 2013-03-21 | Targacept Inc | （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型 |
| US8017785B2 (en) | 2006-05-09 | 2011-09-13 | Astrazeneca Ab | Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine |
| WO2008028903A2 (en) | 2006-09-04 | 2008-03-13 | Neurosearch A/S | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
| US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
| US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| UY30846A1 (es) | 2006-12-30 | 2008-07-31 | Abbott Gmbh & Amp | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos |
| JP2010535237A (ja) * | 2007-07-31 | 2010-11-18 | ターガセプト・インコーポレイテッド | （２ｓ）−（４ｅ）−ｎ−メチル−５−（３−（５−イソプロポキシピリジン）イル）−４−ペンテン−２−アミンの経皮投与 |
| CA2707669C (en) | 2007-12-07 | 2016-07-05 | Wilfried Braje | 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases |
| US8703774B2 (en) | 2007-12-07 | 2014-04-22 | AbbVie Deutschland GmbH & Co. KG | Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases |
| US8703775B2 (en) | 2007-12-07 | 2014-04-22 | AbbVie Deutschland GmbH & Co. KG | Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses |
| CA2707671C (en) | 2007-12-07 | 2016-02-02 | Abbott Gmbh & Co. Kg | 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases |
| US8383657B2 (en) | 2007-12-21 | 2013-02-26 | Abbott Laboratories | Thiazolylidine urea and amide derivatives and methods of use thereof |
| WO2009146031A1 (en) | 2008-03-31 | 2009-12-03 | University Of South Florida | Methods of treating disease-induced ataxia and non-ataxic imbalance |
| EP2435080A2 (en) | 2009-05-29 | 2012-04-04 | Abbott Laboratories | Pharmaceutical compositions for the treatment of pain |
| CN103180277A (zh) * | 2010-05-20 | 2013-06-26 | 塔格塞普特股份有限公司 | 制备芳基取代的烯属胺的新方法 |
| WO2013184732A1 (en) * | 2012-06-06 | 2013-12-12 | Targacept, Inc. | Crystalline (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]4-penten-2-amine 1,5-naphthalenedisulfonate |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5242935A (en) * | 1992-03-06 | 1993-09-07 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5597716A (en) * | 1993-11-18 | 1997-01-28 | Mitsubishi Rayon Co., Ltd. | Process for producing D-lactic acid and L-lactamide |
| WO1996020600A1 (en) * | 1995-01-06 | 1996-07-11 | R.J. Reynolds Tobacco Company | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
| US5597919A (en) * | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| US5616707A (en) * | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
| US5585388A (en) * | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| WO1996036637A1 (en) * | 1995-05-17 | 1996-11-21 | R.J. Reynolds Tobacco Company | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
| US5616716A (en) * | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
| JP4357001B2 (ja) * | 1996-04-23 | 2009-11-04 | ターガセプト，インコーポレイテッド | 中枢神経系障害の予防及び治療のための医薬組成物 |
| US5629325A (en) * | 1996-06-06 | 1997-05-13 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
| DE69825879T2 (de) * | 1997-02-21 | 2005-09-01 | Targacept, Inc. | Pharmazeutische zusammensetzungen welche aryl-substituierte olefinische amin-verbindungen enthalten |
| CA2709735A1 (en) * | 1998-06-16 | 1999-12-23 | Targacept, Inc. | Aryl substituted olefinic amines and their use as cholinergic receptors agonists |
-
1999
- 1999-06-03 CA CA2709735A patent/CA2709735A1/en not_active Abandoned
- 1999-06-03 ES ES99926152T patent/ES2228054T3/es not_active Expired - Lifetime
- 1999-06-03 DE DE69919537T patent/DE69919537T2/de not_active Expired - Lifetime
- 1999-06-03 AT AT99926152T patent/ATE273956T1/de active
- 1999-06-03 WO PCT/US1999/012340 patent/WO1999065876A1/en not_active Ceased
- 1999-06-03 CA CA002677519A patent/CA2677519A1/en not_active Abandoned
- 1999-06-03 BR BR9911325-2A patent/BR9911325A/pt not_active Application Discontinuation
- 1999-06-03 AU AU42307/99A patent/AU4230799A/en not_active Abandoned
- 1999-06-03 DK DK99926152T patent/DK1086082T3/da active
- 1999-06-03 JP JP2000554703A patent/JP4240815B2/ja not_active Expired - Fee Related
- 1999-06-03 CA CA002334923A patent/CA2334923C/en not_active Expired - Fee Related
- 1999-06-03 EP EP99926152A patent/EP1086082B9/en not_active Expired - Lifetime
- 1999-06-03 PT PT99926152T patent/PT1086082E/pt unknown
- 1999-06-03 KR KR1020007014279A patent/KR100593433B1/ko not_active Expired - Fee Related
-
2008
- 2008-05-19 JP JP2008130504A patent/JP4896923B2/ja not_active Expired - Fee Related
- 2008-05-19 JP JP2008130502A patent/JP4972608B2/ja not_active Expired - Fee Related
-
2010
- 2010-06-15 JP JP2010135746A patent/JP2010229149A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002518373A5 (https=) | ||
| JP2003503454A5 (https=) | ||
| AU2002216097A1 (en) | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism | |
| MXPA03005155A (es) | 1,2-difenilazetidinonas novedosas, procesos para su preparacion, farmacos que contienen compuestos y su uso para el tratamiento del metabolismo afectado de los lipidos. | |
| AU2001233299A1 (en) | Methods for treating alzheimer's disease | |
| SG158731A1 (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
| GB0403037D0 (en) | Pharmaceutical compounds | |
| EE200200716A (et) | Ühendid Alzheimeri tõve käitluseks | |
| ITTO20000303A0 (it) | Procedimento per l'animazione di un modello sintetizzato di volto umano pilotata da un segnale audio. | |
| JP2002501025A5 (https=) | ||
| AU2003206413A1 (en) | Substituted amino carboxamides for the treatment of alzheimer's disease | |
| DK0628548T3 (da) | 1,2,3,4-Tetraydro-acridinamin-derivater | |
| JP2005509503A5 (https=) | ||
| CA2301706A1 (en) | Use of phanquinone for the treatment of alzheimer's disease | |
| ZA906057B (en) | 4-(n-substituted amino)-2-butynyl-1-ureas and thioureas and derivatives thereof as centrally acting muscarinic agents | |
| FR2793490B1 (fr) | Procede de preparation du (1r,2s,4r)-(-)-2-[(2'-{n,n- dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]- bicyclo[2.2.1]-heptane et ses sels d'addition d'acide pharmaceutiquement acceptables | |
| JP2007506784A5 (https=) | ||
| AU2003299101A1 (en) | Compounds for the treatment of alzheimer's disease | |
| JP2003501387A5 (https=) | ||
| CA2436537A1 (en) | Pharmaceutical compositions comprising tiotropium salts and antihistamines | |
| AU2001267826A1 (en) | Remedies for alzheimer's disease | |
| AU2003260745A1 (en) | Sulphonylamino derivatives for the treatment of alzheimer's disease | |
| AU2001294378A1 (en) | Process for the preparation of enantiomerically enriched amines | |
| JP2000290184A5 (https=) | ||
| AU5163799A (en) | Use of alfuzosin for the manufacture of drugs intended for the treatment of disorders induced by smooth muscle contraction in the urinary tract, excluding contraction of alpha-adrenergic origin |